A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese Subjects
| Status: | Completed |
|---|---|
| Conditions: | Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 12/31/2017 |
| Start Date: | January 2011 |
| End Date: | July 2017 |
This study will determine how morbid obesity affects the distribution and metabolism of the
drug propofol. The investigators hypothesize that propofol will be distributed and
metabolized differently in morbidly obese subjects as compared to normal weight subjects.
drug propofol. The investigators hypothesize that propofol will be distributed and
metabolized differently in morbidly obese subjects as compared to normal weight subjects.
Inclusion Criteria:
- adult age (ages 18-70)
- body mass index greater than 40 or between 20-25
- American Society of Anesthesiologists Class I, II, or III
- undergoing elective surgical procedure requiring general anesthesia
Exclusion Criteria:
- evidence of cardiovascular or pulmonary disease
- kidney or liver dysfunction
- drug allergy to propofol
- history of difficult airway
- on prescribed or over the counter anxiolytics, antipsychotics, or sleeping aids
- unable to speak or understand English
We found this trial at
1
site
Stanford University School of Medicine Vast in both its physical scale and its impact on...
Click here to add this to my saved trials
